Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 7-Ethyl-10-Hydroxycamptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 17/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CASP1 | P29466 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL34018 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29787648 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL13420265 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL733477 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL16072280 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29354078 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL27680702 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL28292269 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL1454961 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL30739326 | 0.95 | MEN1 (0.91) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729561-A1 | POLYETHYLENE GLYCOL DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| CN-119235866-B | Application of SN38 and AZ20 in preparation of medicines for treating brain stem glioma | 首都医科大学附属北京天坛医院 | 2025-06-24 | — | — | CN | claimed |
| CN-119950749-A | Polymer-based macromolecular prodrugs | 费城儿童医院 | 2025-05-09 | — | — | CN | claimed |
| CN-119235857-A | Application of SN38 compound in preparation of medicines for treating brain stem glioma | 首都医科大学附属北京天坛医院 | 2025-01-03 | — | — | CN | claimed |
| CN-119235866-A | Application of SN38 and AZ20 in preparation of medicines for treating brain stem glioma | 首都医科大学附属北京天坛医院 | 2025-01-03 | — | — | CN | claimed |
| CN-119173537-A | Modified immunoglobulins Single variable domain | 苏州智核生物医药科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| WO-2024255854-A1 | POLYETHYLENE GLYCOL DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2024-12-19 | — | — | WO | claimed |
| CN-118994263-A | Multimode iron death induction molecule and preparation method and application thereof | 南方医科大学珠江医院 | 2024-11-22 | — | — | CN | claimed |
| CN-115611926-B | Non-sensitive bond bridged SN38 dimer prodrug, self-assembled nanoparticle thereof and application thereof | 沈阳药科大学 | 2024-03-12 | — | — | CN | claimed |
| WO-2023191209-A1 | MICELLE INCLUDING HYDROPHILIC PEPTIDE AND USE THEREOF | 주식회사 퓨전바이오텍 | 2023-10-05 | — | — | WO | claimed |
| CN-115594732-A | Linker-drug conjugate, preparation method and application thereof | 泰州复旦张江药业有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| WO-2022229932-A1 | HYPOXIA INDUCIBLE FACTOR (HIF) INHIBITORS FOR TREATMENT OF ATROPHY ASSOCIATED WITH RETINAL HYPOXIA | STEFANSSON EINAR (IS) | 2022-11-03 | — | — | WO | claimed |
| US-20260146082-A1 | BISPECIFIC ANTI-MYOSTATIN AND ACTIVIN A ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF | IBIO, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-117327085-B | SN 38-fatty alcohol prodrug, self-assembled nanoparticle thereof and application thereof | 沈阳药科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122005464-A | Paclitaxel precursor nano-drug and preparation method and application thereof | 浙江理工大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4729561-A1 | POLYETHYLENE GLYCOL DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-11253603-B2 | Polymer-based macromolecular prodrugs | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2022-02-22 | — | — | US | disclosed |
| CN-114073678-A | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253603-B2 | Polymer-based macromolecular prodrugs | PAICS, PNKP, NAMPT | TOP1 117/4885MEN1 435/4885KMT2A 2170/4885 |
| US-20260146082-A1 | BISPECIFIC ANTI-MYOSTATIN AND ACTIVIN A ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF | MSTN, MST1R, MYOF | TOP1 1867/4885MEN1 690/4885KMT2A 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.